Food and Drug Administration (FDA) head Scott Gottlieb is reeling in his agency’s outrageous four-year ban on direct-to-consumer genetic testing.
Under the Obama administration, the FDA sent a letter to the genetic testing company 23andMe warning that the company was “marketing the 23andMe Saliva Collection Kit and Personal Genome Service…without marketing clearance or approval in violation of the Federal Food, Drug and Cosmetic Act.” The letter noted that the company’s tests had been providing “health reports on 254 diseases and conditions,” including categories such as “carrier status,” “health risks,” and “drug response.” But not anymore: The folks at 23andMe had little choice but to knuckle under to the agency’s demands and stop testing new customers.
The company was eventually permitted to offer genetic test information on customers’ ancestry and on genes associated with traits like the length of their toes. In early 2015, the agency allowed the company to provide users with results from a trait carrier test for Bloom Syndrome. Prior to the FDA’s ban, the company’s $99 genomic screening test package had included results from 53 trait carrier tests.